Craig-Hallum says to keep buying GeneDx Holdings but has cut its price target from $103 to $66.

WGS · GeneDx Holdings Corp.

The AI's read

The kept rating signals continued confidence, but the lower target shows the analyst now sees less value in the shares. This is one analyst's view, not new evidence about GeneDx's results. The signals point in different directions, so this report alone does not show a clear change in the company's outlook.